\
&
Contact us
\
&
Contact us
Published on | 8 months ago
Programmes Digital Europe Deployment: Best use of technologiesDG CONNECT has launched a procurement for the Development, Consultancy and Support for an Age Verification Solution
Description: This procurement will enable users of online web services to prove their age through the presentation of an electronic attestation through a dedicated application (mobile app) in a privacy preserving manner in order to access age restricted content. This mobile app will directly contribute to the implementation of the provisions on protection of minors of the Digital Services Act (DSA). The application will be built in compliance with the emerging technical specifications of the European Digital Identity Wallet (European Digital Identity · GitHub) and integrated into the common specifications of the European Digital Identity Wallet to be provided by Member States further to Regulation (EU) 1183/2024.
Internal identifier: EC-CNECT/2024/OP/0073
Type of procedure: Open
Estimated value excluding VAT: 4.000.000 EUR
More information on the call and the related documents can be found on the Funding & Tenders Portal.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
